Fulgent Genetics (FLGT) Scheduled to Post Quarterly Earnings on Friday

Fulgent Genetics (NASDAQ:FLGT) is set to announce its earnings results before the market opens on Friday, November 8th. Analysts expect the company to announce earnings of ($0.19) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Fulgent Genetics (NASDAQ:FLGT) last released its quarterly earnings results on Friday, August 2nd. The company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.45. The firm had revenue of $71.03 million for the quarter, compared to the consensus estimate of $69.07 million. Fulgent Genetics had a negative return on equity of 2.75% and a negative net margin of 56.22%. The firm’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same quarter last year, the business posted ($0.33) EPS. On average, analysts expect Fulgent Genetics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Fulgent Genetics Stock Up 5.8 %

NASDAQ:FLGT opened at $21.45 on Friday. The stock’s 50 day moving average price is $21.20 and its 200 day moving average price is $21.39. The company has a market capitalization of $641.87 million, a PE ratio of -3.85 and a beta of 1.50. Fulgent Genetics has a 52-week low of $18.76 and a 52-week high of $30.68.

Insiders Place Their Bets

In other Fulgent Genetics news, CEO Ming Hsieh sold 2,313 shares of the stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $22.83, for a total transaction of $52,805.79. Following the completion of the sale, the chief executive officer now directly owns 707,275 shares of the company’s stock, valued at approximately $16,147,088.25. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last ninety days, insiders sold 4,324 shares of company stock valued at $98,717. 31.76% of the stock is owned by company insiders.

About Fulgent Genetics

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.